Creon 19000 [USP'U]/1 (Pancrelipase CAPSULE, DELAYED RELEASE PELLETS) 19000 [USP'U]/1

Creon 19000 is a prescription medication containing pancrelipase, an enzyme replacement therapy. It is used to treat people who cannot digest food properly due to a lack of pancreatic enzymes. This condition can occur in individuals with cystic fibrosis, pancreatitis, or those who have had their pancreas removed. Creon 19000 works by providing the necessary enzymes to break down food into nutrients that can be absorbed by the body.

Strength

19000 [USP'U]/1

Pack Size

250 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0032-1206-07)

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Creon 19000 is used to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough digestive enzymes. This can lead to malnutrition and poor absorption of nutrients from food. The medication is typically taken with meals to help the body absorb the nutrients from food.

Side Effects

Common side effects of Creon 19000 include abdominal pain, diarrhea, and nausea. In rare cases, the medication can cause an allergic reaction, which may manifest as hives, itching, or difficulty breathing. It is essential to follow the prescribed dosage and consult a doctor if any side effects occur.

Precautions & Warnings

Creon 19000 should be stored at room temperature, away from moisture and heat. The capsules should not be crushed or chewed, as this can cause the enzymes to become inactive. It is also important to handle the capsules carefully to avoid damaging the delayed-release coating.

Avoid Interactions

Creon 19000 may interact with other medications, such as antacids or acid-reducing medications, which can affect the absorption of the enzymes. It is essential to inform a doctor about all medications being taken before starting Creon 19000.

Frequently Asked Questions

The recommended dosage of Creon 19000 varies depending on the individual's condition and response to treatment. It is essential to follow the prescribed dosage and consult a doctor if any questions or concerns arise.

It is essential to inform a doctor about all medications being taken before starting Creon 19000, as it may interact with other medications.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.